View Older Stories View More Recent Stories
-
Maryland Department of Health Partners with Ready Responders to Provide COVID-19 Testing and Medical Evaluations for Residents
-
ARTMS Closes a US$19 Million Series A Financing with Deerfield and Global Health Sciences (GHS) Fund
-
Form 13F-HR DEERFIELD MANAGEMENT For: Mar 31
-
Relode and Ready Responders Announce Partnership to Alleviate Strain During Covid-19 Crisis
-
Endologix Reports First Quarter 2020 Financial Results
-
Nuvo Pharmaceuticals® Announces First Quarter 2020 Results
-
Intersect ENT Announces $65 Million Convertible Notes Investment from Deerfield Management
-
ADC Therapeutics Announces a $115 Million Convertible Credit Facility with Deerfield
-
ADC Therapeutics Announces a $115 Million Convertible Credit Facility with Deerfield
-
DFP Healthcare Acquisitions Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about May 1, 2020
-
Nkarta Therapeutics Appoints Two New Independent Directors
-
Lumos Pharma Hires Biotech Veteran Aaron Schuchart as Chief Business Officer
-
Lumos Pharma Hires Biotech Veteran Aaron Schuchart as Chief Business Officer
-
Melinta Therapeutics Successfully Completes Financial Restructuring
-
Deerfield Closes $840 Million Healthcare Venture Fund
-
Endologix (ELGX) is withdrawing previously issued financial guidance for 2020
-
Endologix Announces Preliminary Financial Results for First Quarter 2020
-
Lumos Pharma Promotes John C. McKew, PhD to Chief Operating Officer and Chief Scientific Officer
-
Lumos Pharma Promotes John C. McKew, PhD to Chief Operating Officer and Chief Scientific Officer
-
Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directors Rick Hawkins, CEO, appointed Chairman of the Board
-
Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directors Rick Hawkins, CEO, appointed Chairman of the Board
-
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2019 Financial Results
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
-
Ready Responders to Provide At-Home Care for Patients and Alleviate Strain on Hospitals During COVID-19 Crisis
-
NewLink Genetics Stockholders Approve Merger with Lumos Pharma
-
NewLink Genetics Stockholders Approve Merger with Lumos Pharma
-
Bridge Medicines Enters Exclusive License Agreement with The Rockefeller University for Novel Epigenetic Leukemia Program
-
DFP Healthcare Acquisitions Corp. Announces Closing of $230 Million Initial Public Offering
-
Sientra Reports Fourth Quarter and Full Year 2019 Financial Results
-
Sientra (SIEN) Announces $60 Million Convertible Notes Investment from Deerfield Management
-
Sientra Announces $60 Million Convertible Notes Investment from Deerfield Management
-
DFP Healthcare Acquisitions Corp. (DFPH) Prices 20M Unit IPO at $10/Unit
-
DFP Healthcare Acquisitions Corp. Announces Pricing of $200 Million Initial Public Offering
-
New Energy Risk, SHINE Medical Technologies Partner on Innovative Insurance Solution That Supports Financing of One-of-a-Kind Nuclear Medicine Facility
-
RubiconMD Secures $18M in Series C Financing Led by Deerfield to Fuel Growth in Primary Care
-
Nuvo Pharmaceuticals® Announces "at risk" Launch of Generic Version of Vimovo in the United States
-
Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company
-
Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company
-
Element Science Raises $145.6 million Series C Financing to Advance Next-Generation Digital Wearable Platform
-
Nuvo Pharmaceuticals® Announces 2019 and Fourth Quarter Results
-
Endologix (ELGX) Announces Debt Restructuring Addressing 2020 Maturities
-
Endologix Announces Debt Restructuring Addressing 2020 Maturities
-
Form 13F-HR DEERFIELD MANAGEMENT For: Dec 31
-
Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed
-
Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed
-
Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed
-
Form 4 Black Diamond Therapeuti For: Feb 03 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Quartet Health Announces New Effort to Improve Access to Mental Health Care and Patient Health Outcomes
-
Passage Bio Appoints Bruce Goldsmith, Ph.D. as Chief Executive Officer

